Digital Health

Digital health sits at the intersection of healthcare's massive inefficiency and technology's ability to automate, predict, and personalize at scale. With 492 funders actively investing in digital health startups tracked in Superscout's database, the sector has built a deep and specialized investor base that includes dedicated health tech venture funds, life science crossover investors, corporate venture arms of health systems, insurers, and pharmaceutical companies, and generalist firms with healthcare mandates. Digital health exists as a child sector within Superscout's broader Healthcare category (7,986 funders), reflecting its specific focus on software, data, and connected technologies that improve clinical care, operational efficiency, and patient experience. Digital health investment reached $14.2 billion in 2025, up 35% from the prior year and the highest total since 2022, though this recovery masks a dramatic bifurcation between well-funded winners and a struggling long tail.

The 2025-2026 digital health market is best described as "a tale of two markets": a clear separation between the "haves" and "have-nots" as fewer companies capture more of the available capital. AI-enabled companies took 54% of total digital health funding in 2025, up from 37% the prior year, and raised rounds with a 19% premium on average deal size compared with companies not focused on AI. In the first half of 2025, the AI advantage was even more pronounced: AI-enabled healthcare startups captured 62% of all digital health venture funding, raising an average of $34.4 million per round, an 83% premium over non-AI startups. For digital health founders without an AI story, the fundraising environment remains exceptionally challenging.

Superscout's stage data shows 348 funders (71%) at seed, 253 (51%) at pre-seed, 218 (44%) at Series A, 111 (23%) at Series B, and 91 (18%) at growth equity. The median minimum check is $500,000, median maximum is $3 million, and the 75th percentile reaches $15 million. The high Series A ratio (44%) reflects the strong pull-through in digital health: companies that can demonstrate clinical validation and initial customer traction find a receptive Series A market, because health systems and payers are actively seeking technology solutions to manage rising costs and staffing shortages. The growth equity ratio (18%) reflects the increasing number of digital health companies reaching the scale required for growth-stage financing.

The top three funded areas in digital health are non-clinical workflow automation, clinical workflow tools, and data infrastructure, all being rapidly transformed by AI. Healthcare's administrative burden, estimated at $1 trillion annually in the US alone, represents the most immediate and commercially accessible opportunity for AI in healthcare. Revenue cycle management (coding, billing, claims processing, prior authorization), clinical documentation (ambient scribes that automatically generate clinical notes from patient-doctor conversations), scheduling and patient communication, and compliance monitoring are all being automated by AI systems that can process healthcare's unique combination of structured data, unstructured text, regulatory rules, and clinical nuance.

Ambient clinical documentation has become healthcare AI's first breakout category, generating $600 million in revenue in 2025, a 2.4x year-over-year increase. Companies like Abridge, Nabla, and DeepScribe use AI to listen to patient-clinician conversations and automatically generate structured clinical notes, addressing one of the most universal pain points in healthcare: physicians spending two hours on documentation for every hour of patient care. The rapid revenue growth in ambient scribes demonstrates the market dynamics that digital health investors seek: a clearly defined pain point, measurable time savings for the user, a straightforward buyer (the health system or physician practice), and a deployment model that can scale quickly without requiring workflow redesign.

The shift from task automation to agentic AI represents the next frontier for digital health investment. In 2026, healthcare VCs are focused on a fundamentals-first model, prioritizing clinical-grade evidence, regulatory clarity, and proven paths to profitability, with the most significant technology shift being the move from simple task automation to agentic AI. Agentic AI systems in healthcare can autonomously navigate complex insurance rules, identify optimal care pathways, manage prior authorizations end-to-end, and coordinate multi-step clinical processes. The implications are profound: rather than requiring a human to supervise every AI-generated output, agentic systems can operate independently on well-defined tasks, dramatically increasing the leverage that each healthcare worker can achieve.

Clinical decision support and AI-assisted diagnosis represent the highest-impact but most regulatory-complex category within digital health. AI systems that can detect diabetic retinopathy from retinal images, identify cancerous lesions in pathology slides, predict sepsis from vital sign patterns, or flag medication interactions are demonstrating accuracy that meets or exceeds specialist-level performance in defined clinical scenarios. The FDA's AI/ML regulatory framework has evolved significantly, with over 950 AI-enabled medical devices cleared or approved, but the path to market requires rigorous clinical validation, real-world performance monitoring, and navigating a reimbursement landscape that is still catching up to AI capabilities.

Telehealth and virtual care, while no longer the novel category they were during the COVID-19 pandemic, have matured into a permanent and growing component of healthcare delivery. Virtual care utilization has settled at approximately 5-8x pre-pandemic levels for behavioral health and 2-3x for primary care, representing a structural shift in how healthcare is accessed. The investment thesis has evolved from "telehealth as a platform" (which produced commodity video call companies) to "virtual care as a care model" (which combines technology with clinical protocols to deliver specific outcomes at lower cost). Companies like Hinge Health (musculoskeletal care, IPO in 2025), Omada Health (chronic disease management, IPO in 2025), and Spring Health (mental health) demonstrate that the value in virtual care comes from clinical outcomes and cost reduction, not from the telehealth technology itself.

The digital health IPO window reopened in 2025, with five digital health companies going public: Hinge Health, Omada Health, Heartflow, Carlsmed, and Profusa. These IPOs, after years of slow public market activity following the 2021-2022 SPAC-driven digital health bubble, provide critical validation that digital health companies can achieve public-market-viable business models. They also create a liquidity pathway that makes venture investors more willing to deploy capital into the sector, knowing that exits are available beyond M&A.

M&A activity in digital health jumped to 195 deals in 2025, up 61% from 2024, reflecting both consolidation among digital health companies and increasing acquisition appetite from health systems, insurers, pharmaceutical companies, and technology platforms. For health systems, acquiring digital health capabilities is increasingly seen as essential to competing in value-based care models where clinical efficiency and patient engagement directly impact financial performance. For pharmaceutical companies, digital health acquisitions provide patient engagement platforms, real-world evidence collection, and companion digital therapeutics that extend the value of pharmaceutical products.

Healthcare data infrastructure and interoperability represent a foundational investment category that enables everything else in digital health. The US healthcare system generates approximately 30% of the world's data, but most of it remains siloed in electronic health records, claims databases, pharmacy systems, and device data stores that do not communicate with each other. Companies building healthcare data integration platforms, FHIR-based interoperability solutions, clinical data warehouses, and privacy-preserving data sharing infrastructure are addressing the essential plumbing that allows AI, analytics, and care coordination to function. The regulatory tailwind is significant: CMS interoperability rules, the 21st Century Cures Act information blocking provisions, and TEFCA (the Trusted Exchange Framework and Common Agreement) are creating mandatory demand for healthcare data interoperability.

Firms like Flare Capital Partners ($2-15M, healthcare technology investing with co-creation model leveraging payer and provider LP network), Wavemaker Three-Sixty Health ($200K-$1M, investing in healthcare disruptors focused on value-based care), Vertex Ventures HC (all stages, healthcare companies addressing significant unmet medical needs), Wellington Partners ($2-20M, early and growth stage life science including digital health), PACE Healthcare Capital ($1-4M, digital health companies with commercial traction using AI/ML), and 2070 Health (pre-seed through Series A, building patient-centric healthcare companies from scratch) represent the specialized capital supporting digital health innovation.

For digital health founders, the 2025-2026 funding environment demands three things. First, AI-native architecture that delivers measurable clinical or operational impact, not AI as a marketing label. Second, clear buyer identification and sales motion: knowing whether the customer is a health system, insurer, employer, pharmaceutical company, or consumer, and having validated demand from that buyer. Third, a path through healthcare's unique regulatory and reimbursement landscape: understanding FDA requirements for clinical AI, CPT code availability for reimbursement, HIPAA compliance for data handling, and state-by-state licensing for clinical services. The digital health sector offers the combination of enormous market size ($4+ trillion US healthcare spending), structural inefficiency that creates massive room for technology impact, and regulatory complexity that creates competitive moats for companies that navigate it successfully.